Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pathologic diagnosis of lung NSCLC or squamous cell carcinoma.~2. Patients are to be treated with hypofractionated RT.~3. Patient is not a surgical candidate due to medical comorbidities determined by a thoracic surgeon or patient refusal~4. Patient plans to receive treatment at MD Anderson~5. Patients must sign informed consent~6. Patient must have adequate renal function within 30 days prior to registration, defined as serum creatinine within normal institutional limits or creatinine clearance at least 60 ml/min~Exclusion Criteria:~1. Patient has: random glucose \>200 mg/dl or is taking an oral hypoglycemic agent or insulin at the time of study entry~2. Patient has a history of lactic acidosis, chronic kidney disease or a creatinine \>/= 1.2 mg/dl~3. Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to the participant, embryo, fetus, or nursing infant~4. Patients with history of allergic reaction to metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body Radiotherapy (SBRT) + Metformin (Type: EXPERIMENTAL): Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
- Stereotactic Body Radiotherapy (SBRT) + Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).